Objective

Combining immunotherapeutic antibodies for treatment of cancer patients has shown benefits over single agent treatment. However an attractive alternative is the development of bispecific antibodies that not only address two pharmacological targets but may also result in novel biological mechanisms that are impossible to attain with combinations. A murine-specific anti-LAG-3 and PD-L1 bispecific antibody was engineered which binds both antigens simultaneously and with nanomolar affinities. This potency translates into in vivo efficacy, where the anti-LAG-3/PD-L1 bispecific antibody decreased tumour burden in the MC38 colon carcinoma model.